Rheumatologist Ellen Ginzler, MD, MPH, and nephrologist German Hernandez, MD, FASN, FACP, provide an overview of systemic lupus erythematosus and lupus nephritis. Ellen Ginzler, MD, MPH: SLE, or ...
Antibody-binding of blood dendritic cell antigen 2 (BDCA2), which is expressed exclusively on plasmacytoid dendritic cells, suppresses the production of type I interferon that is involved in the ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Maureen A. McMahon ...
Deucravacitinib reduces circulating proteins associated with kidney dysfunction in patients with systemic lupus erythematosus, according to data presented at ACR Convergence 2025.“Specific plasma ...
FLORENCE — HopeHealth announced Aug. 29 it is participating in a pivotal phase 3 clinical research study, sponsored by global pharmaceutical company Bristol Myers Squibb, to evaluate an ...
Phase I/II data for rese-cel point to its therapeutic potential in systemic lupus erythematosus and lupus nephritis, as well ...
The sense of smell is a complex process of the central nervous system that involves specific areas of the brain. In fact, olfactory dysfunction is seen in various central nervous system disorders that ...
Blood dendritic cell antigen 2 (BDCA2) is a receptor that is exclusively expressed on plasmacytoid dendritic cells, which are implicated in the pathogenesis of lupus erythematosus. Whether treatment ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback